News and Reports
-
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
25 November 2020Download -
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis
23 November 2020Download -
Enhancing Market Position in the Synthetic Biology Industry to Promote High End Biologically Manufactured Alternatives?A Dialogue with Cathay Biotech Inc. Chairman Liu Xiucai
20 November 2020Download -
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
16 November 2020Download -
Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics
9 November 2020Download -
Galecto Announces Pricing of Initial Public Offering
29 October 2020Download -
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
28 October 2020Download -
Dren Bio Announces a $60M Series A Financing
16 October 2020Download -
Cathay Biotech to Invest USD596.5 Million in Northwest China's Largest Synthetic Biology Project
12 October 2020Download -
New CEO Joins Karius to Lead Next Growth Phase
6 October 2020Download -
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Ro
29 September 2020Download -
Sanofi Completes Principia Biopharma Inc. Acquisition
28 September 2020Download -
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
28 September 2020Download -
Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform
24 September 2020Download -
Novellus Closes $57M Series C Financing
21 September 2020Download -
Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million
16 September 2020Download -
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
15 September 2020Download -
NiKang Therapeutics Completes $50 Million Series B Financing
14 September 2020Download -
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA
8 September 2020Download -
Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics
8 September 2020Download -
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
24 August 2020Download -
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
24 August 2020Download -
iTeos Therapeutics Announces Pricing of Initial Public Offering
23 July 2020Download -
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
22 July 2020Download -
Bioatla Raises $72.5 Million in Series D Financing
15 July 2020Download